Search - tctmd.com

Displaying 121 - 140 of 159

Sort: Relevancy | Date

Presentation TCT 2014

Antiplatelet Management Before Non-cardiac Surgery

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Davide Capodanno

September 14, 2014

Presentation TCT 2014

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Freek W.A. Verheugt

September 14, 2014

Presentation TCT 2014

Featured Lecture: First Presentation of the PLATO Primary PCI Subgroup

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Philippe Gabriel Steg

September 14, 2014

Presentation TCT 2014

How Might Genetic and Platelet Function Testing Be Rationally Used TODAY?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Paul A. Gurbel

September 14, 2014

Presentation TCT 2014

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Matthew J. Price

September 14, 2014

Presentation TCT 2014

De-escalating Antiplatelet Treatment in ACS Patients: New Concepts and Upcoming Studies

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Dirk Sibbing

September 14, 2014

Presentation TCT 2014

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Anthony A. Bavry

September 14, 2014

Presentation TCT 2014

Yes: In Select Trials When the Patient Is Stable, Postprocedural Consent Optimizes Understanding and Enrollment!

Presenter: Robert A. Harrington

September 14, 2014

News Conference News ESC 2014

FAME 2: FFR-Guided PCI Continues on Same Trajectory from 1 to 2 Years

Caitlin E. Cox

September 02, 2014

News Industry News

ANTI-CLOTTING AGENT HELPS REDUCE THE INCIDENCE AND IMPACT OF STENT THROMBOSIS DURING PERCUTANEOUS CORONARY INTERVENTION

March 27, 2014

News Conference News AHA 2013

AHA 2013: Mix of Positive, Negative Trials Help Guide Interventional Practice

November 24, 2013

Presentation TCT 2013

Cangrelor Will Be the Answer for Most in the Acute Setting!

Presenter: Robert Harrington

October 31, 2013

Presentation TCT 2013

From Evidence-Based Medicine to Guidelines (and Appropriate Use Criteria) to Clinical Practice

Presenter: Robert Harrington

October 30, 2013

Presentation TCT 2013

The New Medical Enviroment: From Teaching to Patient Care

Presenter: Robert Harrington

October 28, 2013

News Industry News

Anti-Clotting Agent Helps Reduce the Risk of Intraprocedural Events during Percutaneous Coronary Intervention

October 28, 2013

Presentation TCT 2013

Rapid-Acting Potent IV P2Y12 Inhibition: Evolution or Revolution?

Presenter: Robert Harrington

October 27, 2013

News Industry News

FDA Accepts the Filing of The Medicines Company's New Drug Application for Intravenous Antiplatelet Agent Cangrelor

July 01, 2013

News Conference News AHA 2012

AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community

Jason Kahn

November 11, 2012

Presentation TCT 2012

Part 2: Antiplatelet Agents

Presenter: Robert Harrington

October 25, 2012

Presentation TCT 2012

Ticagrelor Update: PLATO: Recent Analyses

Presenter: Robert Harrington

October 24, 2012

Advertisement

Antiplatelet Management Before Non-cardiac Surgery

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Featured Lecture: First Presentation of the PLATO Primary PCI Subgroup

How Might Genetic and Platelet Function Testing Be Rationally Used TODAY?

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

De-escalating Antiplatelet Treatment in ACS Patients: New Concepts and Upcoming Studies

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Yes: In Select Trials When the Patient Is Stable, Postprocedural Consent Optimizes Understanding and Enrollment!

FAME 2: FFR-Guided PCI Continues on Same Trajectory from 1 to 2 Years

ANTI-CLOTTING AGENT HELPS REDUCE THE INCIDENCE AND IMPACT OF STENT THROMBOSIS DURING PERCUTANEOUS CORONARY INTERVENTION

AHA 2013: Mix of Positive, Negative Trials Help Guide Interventional Practice

Cangrelor Will Be the Answer for Most in the Acute Setting!

From Evidence-Based Medicine to Guidelines (and Appropriate Use Criteria) to Clinical Practice

The New Medical Enviroment: From Teaching to Patient Care

Anti-Clotting Agent Helps Reduce the Risk of Intraprocedural Events during Percutaneous Coronary Intervention

Rapid-Acting Potent IV P2Y12 Inhibition: Evolution or Revolution?

FDA Accepts the Filing of The Medicines Company's New Drug Application for Intravenous Antiplatelet Agent Cangrelor

AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community

Part 2: Antiplatelet Agents

Ticagrelor Update: PLATO: Recent Analyses

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content